Del17p is a genomic imbalance occurring in 7%-10% of myeloma at diagnosis newly diagnosed myeloma patients (NDMM) and comprises a poor prognostic factor. The goal of this study is to analyze real world data and outcomes among NDMM patients carrying 17p deletion. We report an observational, retrospective, multicenter study. Sixty consecutive patients diagnosed with multiple myeloma in the 8 participating centers diagnosed between 1/2008 and 1/2016 proven to carry 17p deletion by means of fluorescence in situ hybridization (FISH) were identified. Most received a bortezomib-based induction, over half underwent autologous hematopoietic cell transplantation (HCT); 30% of the patients gained early access to new novel agents via clinical trials, access programs or private insurance. Overall response rate (ORR) after induction was 85%; 94% for transplant eligible (TE); and 75% for transplant ineligible (NTE), and declined in subsequent treatment lines, 64% achieved VGPR. Median overall survival (OS) was 43 months; median progression free survival (PFS) was 11 months, 19 months for TE and 7 for NTE. In multivariate analysis: higher M-Spike, presence of extramedullary disease, and >50% of cells baring del17p were associated with adverse PFS; Autologous HCT and higher hemoglobin were associated with longer PFS; OS was 59 months for patients with early access to newer agents. Older age and higher M-Spike levels were associated with adverse OS, Autologous HCT was associated with favorable OS, 59.7 vs 28.7 months for NTE patients.
| I N TR ODU C TI ON
Myeloma is a clonal malignancy of plasma cells. Recent advances in the treatment of myeloma have significantly improved survival, now reaching a median of 8-10 years in standard risk patients. 1 Yet, the subset of patients with high risk disease, accounting for approximately 15% of the newly diagnosed myeloma patients (NDMM), still exhibit an aggressive disease course. 2, 3 Several cytogenetic abnormalities as detected by fluorescence in situ hybridization (FISH) have been associated with high-risk myeloma phenotype. 3 Among these, deletion of 17p (del17p), is one of the factors conferring the worst outcome with early progression and compromised survival, though clinical course may vary considerably among patients. [4] [5] [6] [7] [8] [9] Del17P has been recognized as a component of the baseline revised international staging system (r-ISS) for myeloma risk stratification. 10 It is detected in approximately 10% of NDMM, and may also appear as a late effect during disease progression. 11, 12 The adverse prognosis associated with this chromosomal aberration is thought to be related to the loss of tumor suppressor protein p53, encoded by the TP53 gene at chromosome 17p13. 11, 13 Deletion of TP53 induces clonal immortalization and survival of tumor cells 14 and is associated with oncogenesis, cancer progression, and drug resistance. 15 Treatment effects in del17p subset of NDMM and RRMM patients have been reported within several clinical trials, though the relative low prevalence of del17p limits prospective evaluation. While earlier novel agent therapies yielded poor outcomes, [7] [8] [9] bortezomib maintenance as recently introduced agents and combinations may partially reverse this adverse prognosis. [17] [18] [19] [20] [21] We report real-world data of a retrospective analysis from a multisite (n 5 8) cohort (n 5 60) of NDMM patients with del17p as detected by FISH, analyzing patterns of treatment and response, disease outcomes, and identifying prognostic factors.
| M E TH ODS
The study was conducted in accordance to the declaration of Helsinki and was approved by the institutional ethic committees. Overall survival was assessed as time from diagnosis to death.
| Statistical methods
Continuous variables were described as the mean, median, standard deviation and range of n observations. Categorical data were described with contingency tables including frequency and percent. Individual subject listings were generated and presented. have not died, survival data were censored at the subject's last known alive date. The probabilities of OS and PFS were estimated using the Kaplan-Meier method, and the log-rank test was used to evaluate the differences between groups. For the time to event analyzes, we compared the current cohort with a previously published cohort of non-del 17 myeloma patients matched in their gender, age, r-ISS treated in similar years across Israel. 22 Multivariate analysis was performed using a Cox proportional hazard regression model for OS, We used SPSS version 23, and Prism version 5.0 to perform the analyzes.
| RE S U L TS
We identified 60 patients with Myeloma who met inclusion criteria and were diagnosed between the years 2008-2016. Patient characteristics are detailed in Table 1 . Median age was 62 (range, 37-78) years. Fifty-one percent of the patients had additional cytogenetic abnormalities. Median follow-up for surviving patients was 17 months (range:
2-79 months).
| Disease and treatment characteristics
The most common CRAB phenomenon was the occurrence of lytic lesions (78% of the patients) and 35% of the patients had a stage 3 disease according to the ISS classification. Thirty one patients (51%) had additional cytogentic abnormalities-20% of the patients had concomitantly 1q21 amplification and 15% had translocation (4;14).
Majority of the patients (n 5 53, 88%) were given bortezomib-based induction therapy -of them 72% (n 5 43) were treated with bortezomib/ cyclophosphamide/dexamethasone (VCD). Thirty four patients (60%) proceeded to autologous HCT as part of first line therapy. Patients who proceeded to autologous HCT were younger, compared to those who did not (mean, 58 6 10.2 vs. 68 6 11.8, P 5.0003).
| Subsequent lines, response rate, and duration of response
Median number of lines of therapy was 2 (range: 1-8 Median duration of response decreased from 10 months to first line treatment to 8, 7.5, 3, and 3 months in the second, third, fourth, and fifth line treatment. There was no difference in the incidence of VGPR after induction therapy between the 2 groups (P 5 .137). Four patients (6%) underwent allogeneic HCT-3 patients as a second line treatment and 1 patient at third line treatment.
| Progression free survival and overall survival outcomes
Median PFS was 11 months (95% CI 7.6-14.4) ( Figure 2 ) and rates of progression-free at 24 and 36 months were 24% (95% CI 13%-32%) and 14% (95%CI 3%-17%). These results were statistically significant inferior when compared to a non-del 17 matched cohort (median PFS 11 months vs. 29 months, P 5 .02). Univariate analysis showed that increased level Figure S1 ).
Median OS was 43 (95% CI 27.5-58.5) months ( Figure 2 ) and rates of survival at 24, 36, and 48 months were 71% (95% CI 41%-76%), 58% (95% CI 32%-65%), and 47% (95% CI 21%-63%), respectively. populations. 23 Burden of disease was relatively high, with a median of 55% plasma cells in diagnostic bone marrow, with a large proportion of bone involvement. Almost all patients received a bortezomib based induction (88%).
The ORR to first treatment line in our cohort was 85% for the entire cohort; 75% and 94% in transplanted and transplant ineligible patients respectively. These rates is comparable to that previously reported for bortezomib-based treatment for transplant eligible unselected NDMM. 22, 24 These findings are comparable to bortezomibbased induction in the HOVON-65/GMMG-HD4, 24 reporting 90%
ORR, and in a single center cohort at MD Anderson Cancer Center 8 reporting ORR of 82% post HCT.
Thus, our data suggest that the poor outcome of del17p reflects early relapse and development of resistance while first line response levels appear to be comparable to standard risk patients.
The PFS in our cohort was 11 months and only 24% of patients were progression free at 24 months. PFS was longer among patients who underwent autologous HCT (59% of patients), 19 months, vs 7 months among those treated without transplant. It is noteworthy that this increased PFS was statistically significant in both Log Rank (P 5 .006) and Breslow (P 5 .002). The difference in the p values may suggest a higher impact of transplant on the earlier events of relapse, which in term suggests these patients should be offer transplant early in the course of the disease. Median overall survival in our cohort was 43 months, 79 months in TE patients vs 22 months in NTE patients.
Our PFS was inferior that described by Merz et al., 5 Clinical trials in NDMM treated with a bortezomib based induction generally reported worse PFS and OS for del17p baring patents (Supporting Information Table S1 ). Note that the HOVON-65/GMMG-HD4 24, 25 suggested that bortezomib induction followed by long term bortezomib significantly reduced the negative impact of del17p presence. The heterogeneity in PFS and OS outcomes is expected, based on differences in patient populations and treatment regimens, differences in cutoff thresholds for del17p classification as well as the inherent heterogeneity among del17p patients, our data is within the range of other reports.
Several factors were found to affect PFS and OS in our cohort, related to host (age), disease burden (M-spike, Hemoglobin) and aggressive biology (presence of EMD and del17p in > 50% of plasma cells) ( Table 2 ). The relative size of the del17p baring clone has also been suggested to effect prognosis; yet no clear consensus has been established, with a variability of thresholds applied across recent clinical trials. Moreover, it has been suggested that different thresholds may be relevant for different cytogenetic aberrations. 26 Presence of additional high risk aberrations has been described by others 4, 27 to adversely affect outcomes, yet this phenomenon was not found in our dataset, perhaps due to variability in assessing other FISH abberations between sites and over time.
Autologous HCT was significantly related to improved PFS and OS in our cohort. In TE patients with NDMM, the hallmark of first-line treatment is high-dose therapy and ASCT combined with novel agents.
This strategy has significantly improved PFS and OS. Therefore, it is difficult to address the role of ASCT for high risk cytogenetics, and in particular in del17p patients. 3 In the IFM2009 trial, 28 [17] [18] [19] [20] [21] Access to these therapies has likely contributed to improve outcomes in our high risk group.
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